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Abstract
Background: Chest pain of suspected cardiac origin is a common complaint for presentation at the emergency
department; however only 10% to 13% of patients will have acute myocardial infarction (AMI). This study examined
a decision support ‘rule-out’ algorithm to stratify risk of AMI in these patients.
Methods: Five hundred and forty-eight patients with chest-pain of suspected cardiac origin were recruited. Blood
samples were collected at presentation (t=0) and after 1, 2, 3, 6, 12 and 24 h. Serum troponin I, heart-type fatty acid-
binding protein (H-FABP), myoglobin, carbonic anhydrase III (CAIII), creatine phosphokinase MB isoenzyme (CK-
MB) and glycogen phosphorylase isoenzyme BB (GPBB) were measured using the Randox Cardiac Plus Array;
Troponin T (cTnT), high sensitivity troponin T (hs-cTnT), high sensitivity CRP (hs-CRP), NT-pro-BNP, total
cholesterol, and HDL were measured using a Modular P Analyser. Clinical and demographic information was
recorded for each patient.
Results: For biomarker analysis, STEMIs were excluded, leaving 360 patients at presentation (72 NSTEMI and
288 non-AMI) and 320 patients at 1 h (66 NSTEMI and 254 non-AMI). A rule-out algorithm was developed based on
H-FABP and hs-cTnT. When the H-FABP hs-cTnT combination algorithm was applied to the data, 106 additional
patients at presentation were identified as non-AMI compared to the standard ESC algorithm, 189/288 (65.6%) vs.
83/288 (28.8%) (p<0.0005), respectively. Furthermore, the H-FABP hs-cTnT combination algorithm, identified 71%
of non-AMI patients at 1 hour with no false negatives.
Conclusion: Deployment of the H-FABP hs-cTnT combination algorithm at the emergency department could
assist in the identification of non-AMI patients at presentation with the potential to reduce the number of hospital
admissions by 106/288 (36.8%). Using the H-FABP hs-cTnT combination algorithm would have a significant impact
on patient health ensuring that the appropriate care and efficient use of resources are directed to patients identified
as high risk.
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Introduction
Chest-pain is a common complaint for presentation at the
emergency department; however only 10% to 13% will have acute
myocardial infarction (AMI). The diagnosis of AMI is by clinical
history, examination, ECG and measurement of cardiac biomarkers,
e.g. hs-cTnT [1]. High sensitivity-cTnT is less specific than
conventional troponins [1,2] and is not effective at ruling out AMI at
presentation [3].
Patients presenting to the emergency department with chest pain of
suspected cardiac origin that have ST elevations (STEMIs) are
optimally managed by primary percutaneous coronary intervention
(primary PCI) and biomarker results are not required for triage.
However, most patients present with chest pain and nonspecific or
normal ECG findings and the diagnosis of AMI is aided by
measurement of cardiac biomarker changes over at least two time
points. Current diagnostic algorithms employed in emergency
departments do not exhibit sufficient specificity to rule-out AMI at
presentation [4]. An earlier exclusion of AMI in the emergency
department would avoid prolonged patient observation and in some
cases, hospital admission for measurement of sequential cardiac
biomarkers.
Heart-type Fatty Acid-Binding Protein (H-FABP) is present in high
concentrations unbound in the cytoplasm of myocardiocytes. The
stability and solubility of H-FABP together with its low molecular
weight (15 kDa compared with 18, 37, and 80 kDa for myoglobin, cTnT
and creatine phosphokinase MB isoenzyme (CK-MB), respectively
[5]), its rapid release into plasma after myocardial injury (30 min after
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FABP a suitable candidate biomarker to investigate for the early
diagnosis of AMI. We hypothesized that H-FABP could aid in the
diagnosis of, and ruling out of, early AMI.
The study aimed to identify an algorithm to rule-in and/or rule-out
AMI in patients who present at the emergency department with chest
pain of suspected cardiac origin. Too many patients have prolonged
waits for diagnosis. Deployment of the proposed algorithm at the
emergency department would provide evidence-based decision-
making to clinicians enabling them to stratify and manage risk in these
patients. The algorithm used biomarker measurements at presentation
and at 1 hour to assist with the diagnosis and ruling out AMI. The
algorithm was developed using retrospective data.
Materials and Methods
Patient population
Patients with chest pain of presumed cardiac origin presenting to
the emergency department in Craigavon Area Hospital or Daisy Hill
Hospital, UK between October 2009 and October 2011, were recruited
to the Rapid Diagnosis and Risk Stratification of Acute Coronary
Syndromes (RADAR ACS) study (ISRCTN60873148).
Patients over 18 years of age with ischaemic-type chest pain were
included. Patients were excluded if symptom onset was greater than
12h prior to recruitment, they had a terminal malignancy, received
thrombolysis prior to recruitment, were receiving chronic
anticoagulant therapy, or had previously been recruited into the study.
Time of symptom onset was determined following patient interview.
A 12-lead ECG was obtained for all patients on presentation. Blood
samples were collected at presentation and at subsequent time points.
Diagnosis of AMI was established according to the universal definition
of AMI at the time of the study [8]. Final diagnosis was adjudicated by
two independent clinicians who had access to the clinical, laboratory
and imaging data.
The study complied with the Declaration of Helsinki, was approved
by the Office for Research Ethics Committee Northern Ireland and the
Southern Health and Social Care Trust Research and Development
Department and written informed consent was obtained from all
participating patients. The study complied with Standards for
Reporting Diagnostic Accuracy (STARD) guidelines [9].
Blood sampling and laboratory methods
Blood samples were collected at presentation (t=0) and after 1, 2, 3,
6, 12 and 24 h. Samples were immediately centrifuged and serum
aliquots stored at -80°C. Troponin I (cTnI), H-FABP, myoglobin,
carbonic anhydrase III (CAIII), glycogen phosphorylase isoenzyme BB
(GPBB) and CK-MB were measured simultaneously for all the time
points using the Cardiac Plus Array, Evidence Investigator platform
(Randox Laboratories Ltd, Crumlin, County Antrim, UK). Remaining
biomarkers, cTnT, high sensitivity troponin T (hs-cTnT), high
sensitivity C-reactive protein (hs-CRP), NT-pro-BNP, total cholesterol,
and HDL/LDL were measured using Roche assays and the Roche
Modular P Analyser (Roche Diagnostics, Basel, Switzerland).
N.B. after the biomarker results had been analysed, the hospital
laboratory was informed by Roche that the batches of hs-cTnT used in
the study had been compromised by a calibration shift [10]. As such,
fresh aliquots of patient sample were re-measured using new hs-cTnT
assays and the results reanalysed. As a result, this contributed to the
missing values noted in the study.
Statistical analyses and feature selection
Areas under the receiver operator curve (AUROC) were initially
evaluated to compare different biomarkers for segregating cases of
AMI from non-AMI. The biomarkers were measured at different time
points and statistical comparisons of their AUROC were carried out
using R version 3.1.0 package “pROC” [11]. The biomarkers exhibiting
the highest AUROC where chosen as candidate biomarkers for further
exploration. Patients with missing values were excluded from the
analyses. The statistical analysis used for comparing algorithms was
Net Reclassification Improvement (NRI) [12]. For comparison between
groups, the Fisher's exact and Mann-Whitney U test were applied. A
p<0.05 was considered statistically significant.
Results
Baseline characteristics
Five hundred and forty-eight patients with suspected ischemic chest
pain were included in the study. Patient demographics and biomarkers
measurements at presentation are shown in Table 1. One hundred and
sixty-seven patients were diagnosed AMI (167/548 (30.5%)); 97/167
(58.1%) patients were diagnosed NSTEMI.










Male sex, n (%) 128 (76.6) 253 (66.4) 0.020
Cardiovascular Risk Factors
Hypertension, n (%) 98 (57.7) 221 (58.0) 0.925
Hyperlipidemia, n (%) 115 (68.9) 287 (75.3) 0.117
Diabetes, n (%) 34 (20.4) 69 (18.1) 0.720
Current smoker, n (%) 52 (31.1) 69 (18.1) 0.001
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Former smoker, n (%) 53 (31.7) 152 (39.9) 0.084
History of CAD
Family History of CAD, n (%) 75 (44.9) 209 (54.9) 0.033
Past Angina, n (%) 64 (38.3) 204 (53.5) 0.001
Past EST, n (%) 42 (25.1) 160 (42.0) 0.000
Past non-IR, n (%) 62 (37.1) 207 (54.3) 0.000
Past Angiogram, n (%) 4 (38.3) 188 (49.3) 0.020
Past PCI, n (%) 36 (21.6) 101 (26.5) 0.239
Past CABG, n (%) 16 (9.6) 31 (8.1) 0.620
LBBB, n (%) 11 (6.6) 13 (3.4) 0.112
Vital Parameters
Systolic BP, mmHg, mean (range) 140.4 (72-219) 137.5 (85-234) 0.176
Diastolic BP, mmHg, mean (range) 78.9 (49-128) 77.2 (34-130) 0.455
Heart rate, bpm, mean (range) 76.2 (40-140) 75.4 (40-180) 0.545
ECG Rhythm
ST-segment shift, n (%) 85 (50.9) 21 (5.5) 0.000
T-wave inversion, n (%) 21 (12.6) 25 (6.6) 0.028
Laboratory Results
Creatinine, μmol/min (range) 98.1 (52.6-266.8) 92.1 (39.8-223.9) 0.079
Biomarker Results
cTnT, ng/l, mean (range) 0.2 (0.00-2.9) 0.01 (0.0-1.2) 0.000
hs-cTnT, ng/l, mean (range) 202.9 (0.0-3399) 16.3 (0.0-1140) 0.000
H-FABP, μg/l, mean (range) 19.7 (0.7-100.0) 2.6 (0.0-72.3) 0.000
CK-MB, μg/l, mean (range) 10.2 (0.6-100.0) 2.3 (0.0-51.0) 0.000
Myoglobin, μg/l, mean (range) 149.9 (5.4-700.0) 45.3 (3.7-301.7) 0.000
cTnI, μg/l, mean (range) 0.7 (0.0-35.5) 0.1 (0.0-7.2) 0.000
GPBB, μg/l, mean (range) 18.4 (0.0-213.0) 11.7 (0.0-61.6) 0.000
hs-CRP, mg/l, mean (range) 6.6 (0.01-103.3) 6.7(0.01-215.1) 0.933
CAIII, μg/l, mean (range) 56.4 (8.5-199.0) 50.8 (7.7-199.0) 0.154
NT-proBNP, pg/l, mean (range) 1209.2 (10.2-38355) 440.4 (5.0-8150.0) 0.000
ED: emergency department; CAD: coronary artery disease; EST: exercise stress test; non-IR: non-insulin requiring; LBBB: left bundle-branch block; BP: blood
pressure; ECG: electrocardiogram. aThe definition of AMI includes patients with ST and non-ST-elevation myocardial infarction.
Table 1: Baseline patient characteristics at presentation to emergency department.
STEMI patients (70/167 (41.9%)) were not included in the analyses
(Table 2). Of the n=97 NSTEMI patients, complete data sets were
available for n=72 at presentation and n=66 at 1 hour (t=1). Of the
n=381 non-AMI patients, data was available for n=288 at presentation
and n=254 at 1 h (Figure 1).
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Biomarker AUROC SE (95% CI) p valuea p valueb
hs-cTnT 0.908 0.021 (0.867-0.950) 0.008 NA
H-FABP 0.848 0.024 (0.802-0.895) 0.414 0.059
cTnT 0.820 0.026 (0.768-0.871) NA 0.008
CK-MB 0.797 0.027 (0.744-0.850) 0.556 0.001
Myoglobin 0.730 0.031 (0.668-0.791) 0.028 0.000
cTnI 0.658 0.027 (0.605-0.710) 0.000 0.000
NT-proBNP 0.650 0.033 (0.585-0.715) 0.000 0.000
GPBB 0.577 0.034 (0.510-0.644) 0.000 0.000
hs-CRP 0.536 0.034(0.469-0.602) 0.000 0.000
CAIII 0.526 0.033 (0.459-0.587) 0.000 0.000
SE: Standard Error; CI: 95% confidence interval; acompared to cTnT; bcompared to hs-cTnT; NA: not applicable.
Table 2: Areas under the receiver operating characteristic curve (AUROC) for high-sensitive troponin T (hs-cTnT), heart-type fatty acid-binding
protein (H-FABP), troponin T (cTnT), creatinine phosphokinase MB isoenzyme (CK-MB), myoglobin, troponin I (cTnI), N-terminal pro b-type
natriuretic peptide (NT-proBNP), glycogen phosphorylase isoenzyme BB (GPBB), high sensitivity C-reactive protein (hs-CRP) and carbonic
anhydrase III (CAIII) after exclusion of patients with ST-elevation myocardial infarction.
Figure 1: Patients included in the analyses. STEMI patients (70/167 (41.9%)) were not included in the analyses. Of the n=97 NSTEMI patients,
complete data sets were available for n=72 at presentation and n=66 at 1 h (t=1). Of the n=381 non-AMI patients, data was available for n=288
at presentation and n=254 at 1 h.
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Biomarker diagnostic accuracy
At presentation (t=0), hs-cTnT had the highest AUROC for
diagnosis of NSTEMI (AUC 0.908 CI 95% (0.867-0.950)) followed by
H-FABP (AUC 0.848 CI 95% (0.802-0.895)) (Table 2). Hs-cTnT vs. H-
FABP for identification of NSTEMI patients was not statistically
significant (p=0.06).
Proposed ‘rule-out’ algorithms
Rule-out algorithms were established by focusing on early time
points t=0 and t=1, and a combination of the most promising
biomarkers (hs-cTnT and H-FABP). The algorithms for presentation
(t=0; n=360 patients) and 1 h (t=1; n=320 patients) are described in
Figures 2A and 2B. Thresholds for hs-cTnT were taken from ESC
guidelines [13]. H-FABP cut-offs and delta changes for hs-cTnT were
selected to ensure the algorithm demonstrated high specificity and
sensitivity (close to 1.0) when applied to the study dataset.
Presentation time point
ESC guidelines [13] for suspected NSTEMI suggest rule-out for (i)
hs-cTnT <5 ng/l at presentation (t=0 h); (ii) or hs-cTnT<12 ng/l at
presentation with a delta change <3 ng/l at t=1 h. For suspected
NSTEMI rule-in (i) hs-cTnT >52 ng/l at t=0 h, (ii) or hs-cTnT delta
change t=1 h >5 ng/l (Figure 3).
Figure 2: Proposed decision tree algorithms based on biomarkers of high-sensitive troponin T (hs-cTnT) and heart-type fatty acid-binding
protein (H-FABP) for ruling out NSTEMI patients at presentation (A) and 1 h (B). ESC rule-out algorithms for presentation (C) and 1 h (D).
Units for hs-cTnT and H-FABP are ng/l and µg/l, respectively.
In this study, the three ESC thresholds for hs-cTnT (5, 12 and 52
ng/l) were used in conjunction with two cut-offs for H-FABP (1.7 and
2.88 µg/l) to separate three potential situations when AMI was
suspected at presentation (Figure 2A). From the analyses, we identified
the following criteria to rule-out AMI at presentation:
(a) hs-cTnT <5 ng/l then rule-out AMI (ESC guidelines for
presentation)
(b) hs-cTnT <12 ng/l and H-FABP <2.88 µg/l then rule-out AMI
(c) hs-cTnT >52 ng/l and H-FABP <1.7 µg/l then rule-out AMI
Results for this algorithm at presentation are presented in Table 3
(algorithm A).
Time point 1 hour
For the proposed algorithm at t=1 (Figure 2, algorithm B) there
were two measurements for each biomarker (t=0 and t=1). The two
biomarker measurements were used to calculate an increase (if any), in
absolute values for differences (deltas) and averages. To identify a
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possible AMI (not rule-out AMI) each of the following criteria had to
occur:
(a) hs-cTnT at t=0h ≥5ng/l and,
(b) delta t=0-1h hs-cTnT≥3ng/l or average of H-FABP (t=0-1h)
≥1.24µg/l and,
(c) hs-cTnT t=1h ≥12ng/l or its increase >10% of the average [(t=0 +
t=1)]/2
There were two patients with elevated hs-cTnT and low H-FABP
who required further investigation. To rule-out the suspicion of an
AMI (and confirm the ‘rule out’) we applied the following rules:
(d) average (t=0-1h) hs-cTnT≥52 ng/l and average (t=0-1h) H-
FABP<1.7 µg/l
or
(e) delta hs-cTnT <2% of average (t=0-1h) when average (t=0-1h) of
H-FABP <1.9 µg/l.
Results for this algorithm are presented in Table 3 (algorithm B).
Algorithms for comparisons
The ESC ‘rule-out’ algorithms [13] for presentation and for 1 h
(Figure 2, algorithms C (t=0) and D (t=1)) were compared to the
proposed algorithms (Figure 2A (t=0) and B (t=1)). The statistical
analysis used for comparing algorithms was Pencina’s NRI, data are
shown in Tables 3 and 4. The results demonstrated that the ESC ‘rule-
out’ algorithm at presentation (algorithm C, Table 4) had similar
sensitivity (1.000 vs. 0.958 respectively, net gain 0.046, Table 4) to the
proposed combination algorithm (algorithm A, Table 3) (0 vs. 3 false
negatives, respectively). However, the ESC ‘rule-out’ algorithm was less
specific (0.288), had 205 false positives when compared to the
proposed combination algorithm (algorithm A Table 3) which had a
specificity of 0.656 and only 99 false positives (net gain for non-AMI of
-0.330, Table 4).
Id. Algorithma AMI TP TN FP FN Sen Spec PPV NPV
0 h (presentation)
A H-FABP and hs-cTnT 72 69 189 99 3 0.958 0.656 0.411 0.984
C ESC rule-out 72 72 83 205 0 1.00 0.288 0.260 1.000
0 h-1 h
B H-FABP and hs-cTnT 66 66 181 73 0 1.000 0.713 0.475 1.000
D ESC rule-out 66 63 175 79 3 0.955 0.689 0.444 0.983
Id.: Identifier of algorithm; a Algorithm relates to the decision tree in Figure 2; n: number of patients; AMI: number of NSTEMI patients; TP: number of true positives; TN:
number of true negatives; FN: number of false negatives; FP: number of false positives; Sen: sensitivity; Spec: specificity; PPV: positive predictive value; NPV:
negative predictive value; h: hour.
Table 3: Diagnostic accuracy of decision tree algorithms related to Figure 2, based on biomarkers of high-sensitive troponin T (hs-cTnT) and
heart-type fatty acid-binding protein (H-FABP) for ruling out NSTEMI patients at presentation (n=360) and 1 h (n=320). The ESC rule out
algorithms at 0 hour and 1 hour are included for comparison.
The probability of a resulting NRI to be >0.330 or <-0.330 was low
(p<0.0005), if the hypothesis of NRI zero is assumed. The ESC ‘rule-
out’ for 1 h (Figure 2D) (3 false negatives) was compared to the
proposed combination algorithm (0 false negatives) for the same time
point (Figure 2B) and the results are shown in Tables 3 and 4 for
algorithm D. The proposed combination algorithm had a higher
specificity at both time points (t=0, 0.656 vs. 0.288: t=1, 0.713 vs. 0.689,
respectively).







A H-FABP & hs-cTnT NA NA NA NA
C ESC rule-out 0.046 -0.376 -0.330 0.000
0 h-1 h
B H-FABP & hs-cTnT NA NA NA NA
D ESC rule-out -0.045 -0.026 -0.069 0.031
Id.: Identifier of algorithm; aAlgorithm relates to the decision tree in Figure 2; AMI
refers to NSTEMI patients; NRI: net reclassification index; p value for algorithm
C being compared to algorithm A and for algorithm D being compared to
algorithm B; NA: not applicable; h: hour
Table 4: Statistical comparison using the Pencina’s Net Reclassification
Improvement of the decision tree algorithms related to Figure 2, based
on biomarkers of high-sensitive troponin T (hs-cTnT) and heart-type
fatty acid-binding protein (H-FABP) for ruling out AMI on NSTEMI
data at presentation (n=360) and 1 h (n=320). The ESC rule-out
algorithms at 0 h and 1 h are included for comparison.
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Figure 3: ESC guidelines 0 h/1 h rule-in and rule-out algorithms using high-sensitivity cardiac troponin (hs-cTn) assays in patients presenting
with suspected non-ST-elevation myocardial infarction (NSTEMI) to the emergency department. 0 h and 1 h refer to the time from the first
blood test. NSTEMI can be ruled-out already at presentation, if the hs-cTn concentration is very low. NSTEMI can also be ruled-out by the
combination of low baseline levels and the lack of a relevant increase within 1 h. Patients have a high likelihood for NSTEMI if the hs-cTn
concentration at presentation is at least moderately elevated or hs-cTn concentrations show a clear rise within the first hour. Cut-off levels are
assay specific. Cut-off levels for other hs-cTn assays are in development. *Only applicable if chest pain onset >3 h. +At the time of the
publication of the guideline not yet commercially available (redrawn from [13]).
Discussion
The aim of this study was to provide algorithms to support clinical
management decisions to rule-in and/or rule-out AMI. These
algorithms would aid in the decision-making pathway(s) to either
admit or potentially discharge patients who present at the emergency
department with chest pain of suspected cardiac origin. The algorithms
used retrospective biomarker data measured at presentation and 1 h to
assist with ruling out AMI in NSTEMI patients. The results
demonstrated that measuring a combination of H-FABP and hs-cTnT
in ECG negative patients (NSTEMI) at presentation was more effective
at ruling out AMI than hs-cTnT on its own. Applying this combination
algorithm (Figure 2A) to the data, identified 189 patients with chest
pain who were non-AMI. This combination algorithm had a
significantly higher specificity at presentation (0.656 vs. 0.288)
compared to the ESC algorithm (Figure 2C) which only identified 83
patients as non-AMI. There were three false negative cases using this
combination algorithm. For patient one, the hs-cTnT value at
presentation was 5.66 ng/l and H-FABP was 0.98 µg/l. Patient two
presented three hours after onset of chest-pain with a hs-cTnT of 5.84
ng/l and H-FABP 1.86 µg/l. For this patient, the biomarkers were still
negative six hours after presentation. The third patient Presented 1
hour and 40 minutes after experiencing chest pain with a hs-cTnT 5.3
ng/l and H-FABP 1.35 µg/l. Interestingly there were two patients with
hs-cTnT <12 ng/l who had elevated H-FABP (≥ 2.88 µg/l) who
experienced an AMI and who were correctly identified by the
proposed algorithm.
When the combination algorithm H-FABP and hs-cTnT (Figure 2B)
was applied to the data at 0-1 h, all chest pain patients positive for AMI
were correctly identified (Table 3). However, when the ESC rule-out
0-1 h (Figure 2D) was applied to the data, three patients who were
AMI positive, were not identified (Table 3).
These new findings improve upon our previous work [14,15]
demonstrating the importance or H-FABP and its value, when
measured in combination with hs-cTnT to rule out AMI at
presentation. In comparison with a rule-out algorithm that included
ECG changes with H-FABP and hs-cTnT [16], we demonstrate that our
combination algorithm of H-FABP and hs-cTnT, had comparable
sensitivity (0.955 vs. 0.991, respectively) and NPV (0.984 vs. 0.997,
respectively). Moreover, our combination algorithm had increased
specificity (0.658 vs. 0.593, respectively) and a higher PPV (0.411 vs.
0.350, respectively). In addition, our combination algorithm identified
more patients with chest pain to be non-AMI at presentation
compared to a previous study using only hs-cTnT (65.6% vs. 27.7%,
respectively) [17].
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The H-FABP hs-cTnT combination algorithm employed in this
current study identified 106 additional non-AMI patients vs. the ESC
algorithm at presentation. Deployment of this combination algorithm
to the current data, could have potentially reduced the total number of
hospital admissions by 36.8%. The MACS rule, which comprises eight
variables, including H-FABP and hs-cTnT, only reduced hospital
admissions by 27%. Furthermore, the MACS rule requires complex
calculations necessitating the use of computers [3].
The current study using the H-FABP hs-cTnT combination
algorithm, identified 71% of non-AMI patients at 1 h with no false
negatives. The TRAPID-AMI study, which also used a 0 and 1 h
algorithm, ruled out 63.4% of patients with chest pain as non-AMI.
However, seven false negatives were reported [18,19].
The proposed H-FABP hs-cTnT combination algorithm at
presentation has clinical utility at the emergency department, where
chest pain accounts for up to 20% of all admissions and was the
primary reason for 5.5 million hospital visits in 2008 [20]. In the UK,
patients who present with chest pain account for two-thirds of all
admissions from the emergency department. However, only 25% of
these patients are diagnosed with acute coronary syndrome.
Furthermore, under current clinical guidelines, 6% of chest pain
patients are discharged with missed myocardial damage, and similar
figures are also observed in Europe [21-23].
The H-FABP hs-cTnT combination algorithm, described in this
manuscript, would provide evidence-based decision-making enabling
clinicians to correctly identify non-AMI patients from those
presenting to the emergency department with chest pain at time of
presentation. These non-AMI patients could be investigated for other
causes of their chest pain, or indeed discharged. The H-FABP hs-cTnT
combination algorithm would have an impact on patient health by
allowing the stratification of risk of serious disease in patients
presenting with chest pain. This would ensure that efficient uses of
resources are provided to patients identified as high risk. Adoption of
the H-FABP hs-cTnT combination algorithm could result in savings of
over £300 (€374) per presenting patient with chest-pain [24].
Study limitations
This study looked at the efficacy of a new algorithm-based test for
stratifying risk of AMI in patients presenting at the emergency
department with chest pain of suspected cardiac origin. Although, the
results are very encouraging, the relatively low number of patients
recruited suggests, a larger study could be conducted to verify results.
Conclusions
We have derived a H-FABP hs-cTnT combination algorithm for
ruling out AMI for use in patients presenting to the emergency
department with chest pain of suspected cardiac origin. The algorithm
described could stratify risk in 65.6% of these patients who could
potentially be discharged at presentation. This would reduce the total
number of chest pain patients admitted for further observation by
36.8% when compared to the ESC algorithm, and would represent a
significant health care saving.
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